Management Team « Neurostimulation – Neuros Medical, Inc. Willoughby, OH -

Management Team

Tom Wilder

President and CEO.  Most recently led Sequent Medical, Inc., which was acquired by Terumo Corporation in 2016 for up to $380 million.  Prior to joining Sequent, he was President and CEO of PhotoThera, Inc.  Prior to this, he served as President and CEO of Micro Therapeutics, Inc. (MTIX), which was merged into ev3, Inc. (EVVV) in 2006, at a valuation of $360 million. Earlier in his career, held positions of increasing responsibility at Medtronic, Inc. (MDT).  He currently serves on the Board of Directors of Penumbra, Inc. (PEN) and Endologix, Inc. (ELGX).

Zi-Ping Fang, Ph.D.

Chief Scientific Officer.  PhD in Biomedical Engineering focused on neurostimulation technology from Case Western Reserve University.  Over 25 years of neurostimulation R&D, pre-clinical and clinical research leading to FDA approval, including technology leadership and management and executive responsibility in neurostimulation startup business development and operations including Nevro and NeuroControl.

Barbara Lindsay, BSN

Vice President of Clinical & Regulatory Affairs.  Over 25 years of experience in leading multi-national teams on IDE/GCP clinical studies, as well as in preparing regulatory submission (e.g., IDE, 510(k), PMA, CE Mark).  Prior to joining Neuros, previously served in leadership roles at JenaValve Technology, Benvenue Medical, TherOx, and Johnson & Johnson.  Prior to entering the medical device sector, served in a number of clinical positions as a registered nurse

Melanie Parravi

Vice President of Quality Assurance & Regulatory Compliance.  Most recently, served as Vice President of Quality Assurance & Regulatory Compliance at Sequent Medical, Inc., acquired by Terumo Corporation in 2016, where she was instrumental in the development of the WEB Aneurysm Embolization System and in the procurement of both US and international regulatory approvals.  Prior to this, served as Sr. Director, Quality Assurance for Covidien’s neurovascular division (formerly ev3/Micro Therapeutics, Inc.).  Worked previously for J&J Biosense Webster and Allergan.

Jon J. Snyder

Founder, Chief Business Officer.  Over 25 years of domestic and international management leadership experience in biomedical and healthcare sales, marketing,  operations, and venture capital investment at start-up and Fortune 500 (Top 20) companies including Cyberonics, Cardinal Health, Imalux, and STERIS Corporation.

David Veino

Chief Commercial Officer.  Most recently, served as Vice President of Sales & Marketing (2015-2017) and Vice President of Marketing (2012-2015) at Cardiovascular Systems, Inc. (CSII), where he led the US commercialization strategy for both the Peripheral Vascular and Coronary segments, establishing market leadership in both categories.  Prior to this, held key commercial leadership positions at Globus Medical (GMED), Stryker Interventional Spine (SYK) and other venture capital medical device start-up companies focused in cardiovascular disease.